<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is accepted practice to prescribe beta-blockers in order to retard <z:hpo ids='HP_0001724'>aortic dilatation</z:hpo> and prevent <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> and rupture in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>A critical review of the published pharmacological studies shows this practice to be based on limited evidence </plain></SENT>
<SENT sid="2" pm="."><plain>The data from small clinical and experimental studies with surrogate end points suggest greater potential benefit from alternative drug regimens, and a recent experimental study showed that <z:chebi fb="0" ids="6541">losartan</z:chebi> may interrupt the mechanism of disease as well as deal with its functional consequences </plain></SENT>
<SENT sid="3" pm="."><plain>It is now essential to perform large, collaborative, randomised controlled trials with clinical end points of new treatments in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
</text></document>